cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2009-0-1-26cardiovascular-1236Research ArticleСтатьиARTICLESФункциональное состояние почек и прогнозирование сердечно-сосудистого рискастатьяредакционная20092001200900Функциональное состояние почек и прогнозирование сердечно-сосудистого риска126Copyright © статья р., 20092009статья р.статья р.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1236
.
ReferencesМоисеев B.C., Кобалава Ж.Д. Кардиоренальный синдром (почечный фактор и повышение риска сердечно-сосудистых заболеваний). Клин фармак тер 2002; 11(3):16-8.Моисеев B.C., Кобалава Ж.Д. Кардиоренальный синдром (почечный фактор и повышение риска сердечно-сосудистых заболеваний). Клин фармак тер 2002; 11(3):16-8.Мухин НА., Моисеев B.C., Кобалава Ж.Д. и др. Кардиоренальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек. Тер архив 2004; 6: 39—46.Мухин НА., Моисеев B.C., Кобалава Ж.Д. и др. Кардиоренальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек. Тер архив 2004; 6: 39—46.Мухин НА. Снижение скорости клубочко-вой фильтрации — общепопуляционный маркер неблагоприятного прогноза. Тер архив 2007;6:5-10.Мухин НА. Снижение скорости клубочко-вой фильтрации — общепопуляционный маркер неблагоприятного прогноза. Тер архив 2007;6:5-10.Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003; 42: 1050— 65.Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003; 42: 1050— 65.National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007: 49 (Suppl2):Sl-180.National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007: 49 (Suppl2):Sl-180.Vassalotti JA, Stevens LA, Levey AS. Testing for chronic kidney disease: a position statement from the National Kidney Foundation. Am J Kidney Dis 2007;50(2): 169-80.Vassalotti JA, Stevens LA, Levey AS. Testing for chronic kidney disease: a position statement from the National Kidney Foundation. Am J Kidney Dis 2007;50(2): 169-80.National Kidney Foundation. K/DOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(Suppl 1): SI—266.National Kidney Foundation. K/DOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(Suppl 1): SI—266.Мое S, Drueke T, Cunningham J, et al. Kidney Disease: Improving Global Outcomes (KDIGO). Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67: 2089-100.Мое S, Drueke T, Cunningham J, et al. Kidney Disease: Improving Global Outcomes (KDIGO). Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67: 2089-100.Brosius FC III, Hostetter TH, Kelepouris E, et al. AHA Science advisory on detection of kidney disease in patients with or at increased risk of cardiovascular disease. Circulation 2006; 114: 1083-7.Brosius FC III, Hostetter TH, Kelepouris E, et al. AHA Science advisory on detection of kidney disease in patients with or at increased risk of cardiovascular disease. Circulation 2006; 114: 1083-7.Смирнов А.В., Добронравов В.А., Каюков И.Г. Проблема хронической болезни почек в современной медицине. Артер гиперт 2006; 12(3): 185-93.Смирнов А.В., Добронравов В.А., Каюков И.Г. Проблема хронической болезни почек в современной медицине. Артер гиперт 2006; 12(3): 185-93.Шилов Е.Н., Фомин В.В., Швецов М.Ю. Хроническая болезнь почек. Тер архив 2007; 6: 75-8.Шилов Е.Н., Фомин В.В., Швецов М.Ю. Хроническая болезнь почек. Тер архив 2007; 6: 75-8.Томилина Н.А., Бигбов Б.Т. Эпидемиология хронической почечной недостаточности и новые подходы к классификации и оценке тяжести хронических прогрессирующих заболевания почек. Тер архив 2005; 6: 87—92.Томилина Н.А., Бигбов Б.Т. Эпидемиология хронической почечной недостаточности и новые подходы к классификации и оценке тяжести хронических прогрессирующих заболевания почек. Тер архив 2005; 6: 87—92.Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-70.Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-70.Stevens AL, Coresh J, Greene T, Levey AS. Assessing Kidney Function — Measured and Estimated Glomerular Filtration Rate. N Engl J Med 2006; 354: 2473-83.Stevens AL, Coresh J, Greene T, Levey AS. Assessing Kidney Function — Measured and Estimated Glomerular Filtration Rate. N Engl J Med 2006; 354: 2473-83.Seliger SL, DeFilippi С Role of Cystatin С as a Marker of Renal Function and Cardiovascular Risk Medscape 26 Oct 2006. www.medscape. comSeliger SL, DeFilippi С Role of Cystatin С as a Marker of Renal Function and Cardiovascular Risk Medscape 26 Oct 2006. www.medscape. comDharnidharka VR, Kwon C, Stevens G. Serum cystatin С is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002; 40: 221-6.Dharnidharka VR, Kwon C, Stevens G. Serum cystatin С is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002; 40: 221-6.Menon V, Shlipak MG, Wang X, et al. Cystatin С as a risk factor for outcomes in chronic kidney disease. Ann Intern Med 2007; 147(1): 19-27.Menon V, Shlipak MG, Wang X, et al. Cystatin С as a risk factor for outcomes in chronic kidney disease. Ann Intern Med 2007; 147(1): 19-27.Рекомендации по профилактике, диагностике и лечению артериальной гипертензии. Российские рекомендации (второй пересмотр). Кардиоваск тер профил2008; 4 (Приложение).Рекомендации по профилактике, диагностике и лечению артериальной гипертензии. Российские рекомендации (второй пересмотр). Кардиоваск тер профил2008; 4 (Приложение).Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-87.Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-87.K/DOQ1 clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43(5Suppl 1): SI—290.K/DOQ1 clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43(5Suppl 1): SI—290.www.fda.govwww.fda.govBoersma C, Atthobari J, Gansevoort RT, et al. Pharmacoeconomics of angiotensin II antagonists in type 2 diabetic patients with nephropathy: implications for decision making. Pharmacoeconomics 2006; 24(6): 523—35.Boersma C, Atthobari J, Gansevoort RT, et al. Pharmacoeconomics of angiotensin II antagonists in type 2 diabetic patients with nephropathy: implications for decision making. Pharmacoeconomics 2006; 24(6): 523—35.Hollenberg NK, Parving H-H, Viberti G, et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 2007; 25: 1921-6.Hollenberg NK, Parving H-H, Viberti G, et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 2007; 25: 1921-6.Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J 2004; 25: 1454-70.Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J 2004; 25: 1454-70.Parving H-H, Persson F, Lewis J, et al. for the AVOID Study Investigators. Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy. N Engl J Med 2008; 358: 2433-46.Parving H-H, Persson F, Lewis J, et al. for the AVOID Study Investigators. Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy. N Engl J Med 2008; 358: 2433-46.Marre M, Puig JG, Kokot F, et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J Hypertens 2004; 22: 1613-22.Marre M, Puig JG, Kokot F, et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J Hypertens 2004; 22: 1613-22.ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-40.ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-40.K/DOQI Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease. Am J Kidney Dis 2003; 41 (Suppl 4): Sl-92.K/DOQI Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease. Am J Kidney Dis 2003; 41 (Suppl 4): Sl-92.Mielniczuk LM, Pfeffer MA, Lewis EF, et al. Estimated Glomerular Filtration Rate, Inflammation, and Cardiovascular Events After an Acute Coronary Syndrome. Am Heart J 2008; 155(4): 725-31.Mielniczuk LM, Pfeffer MA, Lewis EF, et al. Estimated Glomerular Filtration Rate, Inflammation, and Cardiovascular Events After an Acute Coronary Syndrome. Am Heart J 2008; 155(4): 725-31.Shepherd J, Kastelein JJ, Bittner V, et al. TNT (Treating to New Targets) Investigators Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. JACC 2008; 51(15): 1448-54.Shepherd J, Kastelein JJ, Bittner V, et al. TNT (Treating to New Targets) Investigators Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. JACC 2008; 51(15): 1448-54.Shepherd J, Kastelein JJ, Bittner V, et al. Treating to New Targets Investigators.Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol 2007; 2(6): 1131-9.Shepherd J, Kastelein JJ, Bittner V, et al. Treating to New Targets Investigators.Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol 2007; 2(6): 1131-9.Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for imnproving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006; 17: 2006-16.Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for imnproving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006; 17: 2006-16.Wanner C, Krane V, Marz W, et al. Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis. N Engl J Med 2005; 353: 238-48.Wanner C, Krane V, Marz W, et al. Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis. N Engl J Med 2005; 353: 238-48.Fellstrom B, Zannad F, Schmieder R, et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients — design and rationale of the AURORA study. Curr Control Trials Cardiovasc Med 2005; 6: 9.Fellstrom B, Zannad F, Schmieder R, et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients — design and rationale of the AURORA study. Curr Control Trials Cardiovasc Med 2005; 6: 9.Baigent C, Landray MJ. Study of Heart and Renal Protection (SHARP). Kidney Int 2003; 63 (Suppl 84): S207-10.Baigent C, Landray MJ. Study of Heart and Renal Protection (SHARP). Kidney Int 2003; 63 (Suppl 84): S207-10.National Kidney Foundation. K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006; 47(Suppl 3): SI —146.National Kidney Foundation. K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006; 47(Suppl 3): SI —146.Fox KAA, Bassand UP, Mehta SR, et al on behalf of the OASIS 5 Investigatorslnfluence of Renal Function on the Efficacy and Safety of Fondaparinux Relative to Enoxaparin in Non—ST-Segment Elevation Acute Coronary Syndromes. Arm Intern Med 2007; 147:304-10.Fox KAA, Bassand UP, Mehta SR, et al on behalf of the OASIS 5 Investigatorslnfluence of Renal Function on the Efficacy and Safety of Fondaparinux Relative to Enoxaparin in Non—ST-Segment Elevation Acute Coronary Syndromes. Arm Intern Med 2007; 147:304-10.Keech A, Simes RJ, Barter P, et al. FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366(9500): 1849-61.Keech A, Simes RJ, Barter P, et al. FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366(9500): 1849-61.Ansquer JC, Foucher C, Rattier S, et al. DAIS Investigators. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2005; 45(3): 485-93.Ansquer JC, Foucher C, Rattier S, et al. DAIS Investigators. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2005; 45(3): 485-93.Littlewood KJ, Greiner W, Baum D, Zoellner Υ Adjunctive treatment with moxonidine versus nitrendipine for hypertensive patients with advanced renal failure: a cost-effectiveness analysis. BMC Nephrology 2007; 8: 9doi:10.1186/1471-2369-8-9.Littlewood KJ, Greiner W, Baum D, Zoellner Υ Adjunctive treatment with moxonidine versus nitrendipine for hypertensive patients with advanced renal failure: a cost-effectiveness analysis. BMC Nephrology 2007; 8: 9doi:10.1186/1471-2369-8-9.
The authors declare that there are no conflicts of interest present.